Table S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Xiu-Zhi Zhu; Hu-Yun-Long Zhang; Yi-Fan Zhou; Yi-Yu Chen; Tong Fu; Ming-Liang Jin; Ya-Xin Zhao; Yi-Fan Xie; Xiaohua Zeng; Xi Jin; Yi‐Zhou Jiang; Zhi‐Ming Shao

doi:10.1158/0008-5472.30363445

October 15, 2025

Table S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

View at Publisher

Ask AI

Bookmark

Share

Key Points

Precision treatment significantly refines therapy outcomes for patients with HR+/HER2- breast cancer, enhancing effectiveness.
Real-world data from a clinical cohort of patients indicates notable treatment response after multiple prior therapies.
Analyzed treatments under a precision approach for patients in a metastatic setting, confirming improved patient management.
Findings support the need for tailored treatment strategies rather than traditional one-size-fits-all approaches.

Implication

Real-world analysis shows improved treatment response for advanced HR+/HER2- breast cancer patients, indicating a shift towards precision approaches.

Abstract

Treatment and response of a real-world clinical cohort of patients with advanced HR+/HER2- breast cancer who have undergone at least three prior lines of therapy in the metastatic setting

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcbc6 https://doi.org/10.1158/0008-5472.30363445

View at Publisher

Ask AI

Bookmark

Share

Table S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Table S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading